An article in Forbes wonders, does the post-genome drug discovery process need to evolve? One scientist-radical, Peter Sorger of Merrimack Pharmaceuticals, believes it does, and he is working toward a new approach that would discover and test drugs for humans.
The article parades out a series of scientists bemoaning the lack of decent information about the basic network that runs a human being -- and how that complex system must be figured out before really intelligent drug design can be made possible.